Pharvaris (NASDAQ:PHVS) Now Covered by Analysts at Guggenheim

Guggenheim began coverage on shares of Pharvaris (NASDAQ:PHVS - Get Free Report) in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports. The brokerage set a "buy" rating and a $32.00 price target on the stock. Guggenheim's price target points to a potential upside of 91.62% from the company's current price.

A number of other research analysts have also commented on PHVS. Cantor Fitzgerald cut their target price on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Wedbush restated an "outperform" rating and issued a $27.00 target price on shares of Pharvaris in a research note on Thursday, June 5th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $36.20.

Pharvaris Stock Down 3.1%

Shares of PHVS stock traded down $0.53 during trading hours on Wednesday, reaching $16.70. 12,409 shares of the company's stock were exchanged, compared to its average volume of 74,118. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $25.50. The stock has a market capitalization of $873.24 million, a P/E ratio of -5.96 and a beta of -2.86. The business has a fifty day moving average price of $15.93 and a 200-day moving average price of $16.87.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). As a group, research analysts expect that Pharvaris will post -2.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. FMR LLC raised its stake in Pharvaris by 3.6% during the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock worth $103,429,000 after acquiring an additional 189,714 shares in the last quarter. Soleus Capital Management L.P. raised its stake in Pharvaris by 36.2% during the fourth quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock worth $15,617,000 after acquiring an additional 216,483 shares in the last quarter. Octagon Capital Advisors LP raised its stake in Pharvaris by 25.4% during the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock worth $14,914,000 after acquiring an additional 157,530 shares in the last quarter. Rock Springs Capital Management LP raised its stake in Pharvaris by 2.4% during the fourth quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company's stock worth $14,859,000 after acquiring an additional 18,200 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Pharvaris by 36.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after acquiring an additional 118,408 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.